GeoVax reaffirms Q4 start for GEO-MVA pivotal trial, reports $3.1 million cash
GeoVax said it kept working through operational steps for its EMA-backed GEO-MVA immunobridging study while advancing Gedeptin combination plans and narrowing quarterly losses.
GeoVax Labs reported second-quarter 2026 results on July 27, 2026, alongside an update on its GEO-MVA vaccine and Gedeptin oncology programs.
The company said it advanced multiple operational initiatives during the second quarter supporting the expected fourth-quarter initiation of the GEO-MVA pivotal immunobridging study, under an expedited regulatory pathway established through formal Scientific Advice discussions with the European Medicines Agency (EMA)1. Those efforts included clinical operations planning and start-up activities, use of previously manufactured and released cGMP clinical trial material, advancement of the AGE1 continuous cell-line manufacturing platform for future commercial-scale MVA vaccine production, and engagement with government, public health and biodefense stakeholders on orthopoxvirus preparedness and vaccine supply1. GeoVax noted that clinical-grade vaccine has already been manufactured and released under cGMP in preparation for the planned study1.
On the oncology side, GeoVax continued advancing Gedeptin, its investigational gene-directed enzyme prodrug therapy, toward combination strategies designed to enhance immune checkpoint inhibitor activity in solid tumors1. The company said Gedeptin's localized tumor-targeting mechanism and immune activation profile may complement PD-1-based therapies such as Merck's Keytruda by improving responsiveness in immunologically resistant tumors1, and it holds an exclusive license from Emory University covering that combination approach.
Financially, GeoVax posted a net loss of $4,426,578, or $0.97 per share, for the three months ended June 30, 2026, compared with $5,369,783, or $8.74 per share, in the same period of 20251. R&D spending fell to $3,110,508 from $4,728,998 for the comparable quarter1, which the company linked partly to lower costs from discontinued BARDA-related activities and reduced GEO-CM04S1 clinical spending1. In May 2026, GeoVax said it reprioritized its portfolio to focus on GEO-MVA and Gedeptin, discontinuing active development of its GEO-CM04S1 COVID-19 vaccine candidate1, a move it said reflected the shrinking global COVID-19 vaccine market rather than any safety or efficacy issue1.
Cash stood at approximately $3.1 million as of June 30, 2026, compared with $3.1 million at year-end 20251.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.